The small GTPase, Ras, is one of the most frequently mutated oncogenes (20-30%) across all cancers. Ras family members (K-Ras, H-Ras, and N-Ras) regulate diverse biological processes, such as development, growth and protein translation. Dysregulation of Ras contributes fundamentally to the initiation of tumors, the metastatic process and the development of chemoresistance. To this point, Ras oncogenes have stifled direct pharmacological approaches, and inhibitors for the direct effectors of Ras have demonstrated limited or no efficacy within patients. Genetic screens identified point mutations in Kinase Suppressor of Ras (KSR) as potent suppressors of oncogenic Ras, suggesting that KSR could yield novel approaches for Ras-targeted interventions. Although KSR is a member of the protein kinase family, translating KSR mutations into a viable mode of chemical regulation has not yet been practical. KSR belongs to a subclass of protein kinases, termed pseudokinases, which are naturally inactive and therefore belie conventional kinase inhibitor strategies. In recent studies, we identified KSR as a distinct signaling molecule, which functions as a dynamic scaffold of the Ras pathway (Brennan and Dar et al., Nature, 2011). In one state, KSR behaves as an inhibitor of the Ras effector MEK. In another state, KSR is a facilitator of MEK phosphorylation by the kinase immediately downstream of Ras termed RAF. Single point mutations in KSR, which suppress transformation by oncogenic Ras, uncouple the transition between the two states of KSR and suggest novel paths to a chemical suppressor of Ras via KSR. Using structure-based strategies, we will generate small molecules to modulate KSR so that we may stabilize it in distinct conformational states.
We aim to characterize these molecules, and thus the conformational states of KSR, within complex biological systems including engineered cell-based and genetically defined cancer models. Additionally, we will combine our target focused chemistry and profiling with whole animal assays and genetics in the fly. We recently applied this strategy to develop novel therapeutics for Ret-kinase driven cancers (Dar and Das et al., Nature, 2012). Here we will build upon this success to identify molecules that stabilize the Ras-suppressive conformation of KSR as novel treatments for Ras-dependent cancers. Together, this approach will reveal the functional relationship between drug targeting of the pseudokinase KSR and system wide responses within whole animal models of cancer. If successful, this approach will greatly expand opportunities for drug development, reveal regulatory functions and control mechanisms that appear independent of kinase phosphorylation activity, and foster a new paradigm of targeting inactive kinases in diseases including cancer, diabetes, and heart disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
3DP2CA186570-01S1
Application #
9378139
Study Section
Program Officer
Watson, Joanna M
Project Start
2017-04-01
Project End
2018-06-30
Budget Start
2017-04-01
Budget End
2018-06-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Sonoshita, Masahiro; Scopton, Alex P; Ung, Peter M U et al. (2018) A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nat Chem Biol 14:291-298
Levin, Victor A; Abrey, Lauren E; Heffron, Timothy P et al. (2017) CNS Anticancer Drug Discovery and Development: 2016 conference insights. CNS Oncol :
Dhawan, Neil S; Scopton, Alex P; Dar, Arvin C (2016) Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Nature 537:112-116
Levin, Victor A; Tonge, Peter J; Gallo, James M et al. (2015) CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro Oncol 17 Suppl 6:vi1-26
Mendez, Aaron S; Alfaro, Jennifer; Morales-Soto, Marisol A et al. (2015) Endoplasmic reticulum stress-independent activation of unfolded protein response kinases by a small molecule ATP-mimic. Elife 4:
Israelow, Benjamin; Mullokandov, Gavriel; Agudo, Judith et al. (2014) Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors. Nat Commun 5:5408